Physcion 8-O-β-D-glucopyranoside

Physcion 8-O-β-D-glucopyranoside is an anthraquinone compound found in Rumex japonicus Houtt. Physcion 8-O-β-D-glucopyranoside activates ERK/MAP kinase, induces BMP-2 gene expression, and stimulates osteoblast differentiation and mineralization. Physcion 8-O-β-D-glucopyranoside induces cancer cells apoptosis and cell cycle arrest, and shows anticancer activity. Physcion 8-O-β-D-glucopyranoside exerts anti-inflammatory, anti-sepsis, and dementia-ameliorative effects, and induces hepatotoxicity. Physcion 8-O-β-D-glucopyranoside can be used for the research of cancer, inflammation, metabolic and neurological disease^[1][2][3]. In Vitro:Physcion 8-O-β-D-glucopyranoside activates ERK/MAP kinase, Akt kinase, and Runx2, enhances BMP signaling, induces BMP-2 gene expression, and stimulates osteoblast differentiation and mineralization^[1].
Physcion 8-O-β-D-glucopyranoside (5-10 μM; 24-72 h) induces G0/G1 phase cell cycle arrest and apoptosis in NALM6 and SupB15 leukemia cells by modulating cyclin expression, SphK1 activity, and the ceramide/S1P balance^[2].
Physcion 8-O-β-D-glucopyranoside (24-72 h) induces G1 phase cell cycle arrest and dual-pathway apoptosis in HepG2 liver cancer cells, while also inhibiting EMT via ROS/AMPK/Sp1/DNMT1 signaling^[2].
Physcion 8-O-β-D-glucopyranoside (10-20 μM; 24-48 h) induces G0/G1 phase cell cycle arrest and apoptosis in A549 and H358 lung cancer cells by modulating cyclin/CDK expression and activating PPARγ^[2].
Physcion 8-O-β-D-glucopyranoside induces G2/M phase cell cycle arrest and apoptosis in A549 lung cancer cells with an EC₅₀ of 53.01 μg/mL at 24 h and 27.31 μg/mL at 48 h by modulating cyclin B1/Cdc2 signaling and the Bcl-2/Bax ratio^[2].
Physcion 8-O-β-D-glucopyranoside (10-20 μM; 24-48 h) induces G2/M phase cell cycle arrest, apoptosis, and glycolysis inhibition in RCC4 and ACHN renal cancer cells by modulating cyclin/CDK expression and targeting HK2^[2].
Physcion 8-O-β-D-glucopyranoside induces G1 phase cell cycle arrest, apoptosis, and anti-invasion effects in U87 and U251 glioblastoma cells via the ROS/AMPK/mTOR/Skp2 signaling pathway^[2].
Physcion 8-O-β-D-glucopyranoside (10-50 μg/mL; 24-72 h) inhibits EMT and metastasis in MDA-MB-231 breast cancer cells by modulating epithelial/mesenchymal marker expression and targeting AMPK/Sp1/DNMT1 signaling^[2].
Physcion 8-O-β-D-glucopyranoside inhibits EMT and metastasis in HCT116 colorectal cancer cells by modulating epithelial/mesenchymal marker expression and targeting the PTEN/Akt/HIF-1α/EMMPRIN signaling pathway^[2].
Physcion 8-O-β-D-glucopyranoside (50-100 μg/mL; 24-72 h) induces apoptosis in MG-63 osteosarcoma cells via ROS-mediated modulation of the miR-27a/ZBTB10/Sp1/EMMPRIN axis^[2].
Physcion 8-O-β-D-glucopyranoside induces apoptosis in SMMC7221 and Bel-7402 liver cancer cells by downregulating PIM1 and modulating Bcl-2 family protein expression^[2].
Physcion 8-O-β-D-glucopyranoside exerts anti-proliferative effects in SK-MEL-1 and A375 melanoma cells by upregulating miR-124 and downregulating RLIP76 expression^[2].
Physcion 8-O-β-D-glucopyranoside (10-50 μg/mL; 24-72 h) induces apoptosis in KB oral cancer cells via modulation of the miR-21/PTEN/Akt/GSK3β/survivin signaling axis^[2].
Physcion 8-O-β-D-glucopyranoside is cytotoxic to HepG2 cells with an IC₅₀ of 242.27 μM^[3]. In Vivo:Physcion 8-O-β-D-glucopyranoside (20-50 mg/kg; injection; 3 weeks) dose-dependently inhibits MDA‐MB‐231 cells lung metastasis in nude mice via modulation of the AMPK/SP1/DNMT1 pathway^[2].
Physcion 8-O-β-D-glucopyranoside (20-40 mg/kg) exerts anti-leukemic activity in NSI mice, prolonging survival and reducing tumor burden^[2].
Physcion 8-O-β-D-glucopyranoside (40-80 mg/kg) induces apoptosis and delays hepatocellular carcinoma tumor growth in nude mice via modulation of PIM1^[2].